INGESTED INTERFERON ALPHA--BIOLOGIC /CLINICAL EFFECT IN RHEUMATOID ARTHRITIS

这项I期研究的目的是确定是否摄入 干扰素-α（IFN-α）可以减少活动性滑膜炎， 医生对疾病活动性的总体评估和早晨持续时间 类风湿性关节炎是一种自身免疫性疾病。 患者将接受30，000单位的IFN-a隔日治疗， 个月 每两周，将由一名 风湿病学家将进行毒性和免疫功能试验， 在每次门诊访视时进行。 本研究入组了4例患者，现已关闭。 结果 已以手稿形式提交。

The purpose of this Phase I study is to determine whether ingested interferon-alpha (IFN-a) can decrease active synovitis, patient and physician global assessment of disease activity, and duration of morning stiffness in patients with rheumatoid arthritis, an autoimmune disease. Patients will receive 30,000 units of IFN-a on alternate days for two months. Every two weeks, assessment of symptoms will be performed by a rheumatologist. Tests for toxicity and immunological functions will be performed at each clinic visit. Four patients were enrolled in this study, which is now closed. Results have been submitted in manuscript form.